[Federal Register Volume 62, Number 194 (Tuesday, October 7, 1997)]
[Notices]
[Page 52342]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-26499]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made a final finding of scientific misconduct in the 
following case:
    Xiaomin Shang, Ph.D., University of Texas Southwestern Medical 
Center: Based upon a report from the University of Texas Southwestern 
Medical Center, information obtained by the Office of Research 
Integrity (ORI) during its oversight review, and Dr. Shang's own 
admission, ORI found that Dr. Shang, a former postdoctoral fellow 
student in the Department of Obstetrics and Gynecology, University of 
Texas Southwestern Medical Center, engaged in scientific misconduct 
arising out of certain biomedical research supported by a training 
grant from the National Institute of Child Health and Human Development 
(NICHD), National Institutes of Health (NIH).
    Specifically, Dr. Shang fabricated a chemiluminescent film of a 
Western blot by using a physical mask to alter the prior results 
showing lack of antibody specificity to a human steroid metabolizing 
isozyme, rather than replicating an experiment as requested by his 
mentor. The fabricated data were not published.
    Dr. Shang has accepted the ORI finding and has entered into a 
Voluntary Exclusion Agreement with ORI in which he has voluntarily 
agreed, for the three (3) year period beginning September 29, 1997:
    (1) To exclude himself from serving in any advisory capacity to the 
Public Health Service (PHS), including but not limited to service on 
any PHS advisory committee, board, and/or peer review committee, or as 
a consultant; and
    (2) That any institution that submits an application for PHS 
support for a research project on which Dr. Shang's participation is 
proposed or which uses him in any capacity on PHS supported research or 
that submits a report of PHS-funded research in which he is involved 
must concurrently submit a plan for supervision of his duties to the 
funding agency for approval. The supervisory plan must be designed to 
ensure the scientific integrity of Dr. Shang's research contribution. 
The institution also must submit a copy of the supervisory plan to ORI.
    No scientific publications were required to be corrected as part of 
this Agreement.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research 
Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
700, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 97-26499 Filed 10-6-97; 8:45 am]
BILLING CODE 4160-17-P